insights_auto
Why is BMYB34 up 4.45%?
Dive Deeperchevron_right
BMYB34:BVMF
Bristol-Myers Squibb Company BDR
R$331.90
arrow_upward
+4.45%(+14.14) 1D
Sep 30, 4:56:00 PM GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMYB34...
Open
R$331.90
High
R$331.90
Low
R$331.90
Mkt. cap
127.47B
Avg. vol.
49.00
Volume
10.00
52-wk high
R$349.41
52-wk low
R$223.16
Shares outstanding
2.04B
No. of employees
32K
Open
R$331.90
High
R$331.90
Low
R$331.90
Mkt. cap
127.47B
Avg. vol.
49.00
Volume
10.00
52-wk high
R$349.41
52-wk low
R$223.16
Shares outstanding
2.04B
No. of employees
32K
News stories
From web sources and news partners
AD HOC NEWS
·
9 minutes ago
Bristol-Myers Squibb stock: company reports positive Phase 3 ZENBEXUS data
Stock Titan
·
31 minutes ago
Children with this heart condition have one FDA-approved option: Bristol Myers Squibb's CAMZYOS.
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Company BDR
CEOChris Boerner
Employees32.5K
Founded1887
HeadquartersNew York, New York, United States
SectorPharmaceutical industry
Websitebms.com